Small Cell Lung Cancer: Let's connect

Hello all- There is a webinar for Individualized Treatment for Small Cell Lung Cancer sponsored by the Educated Patient through Cure Media group. If you are interested here is the registration form.
https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=&eventid=3336770&sessionid=1&key=41B57549FB15EB15D4CA9D420E79BABE&regTag=&V2=false&sourcepage=register
If you go will you let me know how you like it and if it cleared anything up for you?

We are, thank you. I know a little about immunotherapies, and monoclonal antibodies but until I saw this one in real time, I couldn’t truly grasp the impact it can have on the lives of patients and families. I know they aren’t perfect but no surgery, no radiation, and so far, so good. Our wonderful oncologist says he has a patient who has been on it since clinical trials and still going strong at more than three years. That truly is hope for patients who have previously not had much to hope for.

Chris- What wonderful news! You both must be very excited!

I don’t talk about this a lot, because it isn’t my story to tell, but my brother has small cell lung cancer. He was diagnosed with extensive small cell lung cancer 14 months ago with a primary tumor the size of a mans fist in his his lung and multiple small tumors in the lungs, and liver. He took 4 rounds of chemo with immunotherapy, and has continued with immunotherapy. Tecentric is the immunotherapy drug, every tumor has shrunk to undetectable except the big one which is now very small. We are moving him to an apartment down the street next week and he is selling his house to a friend. The original time frame for him was expected that he could live maybe 8 months but now the doctor says he could live years but no guarantees. We are now getting excited to do things together and squeeze every drop out of life for whatever time he has. I don’t know if this success helps anyone here, but I can hope it does.

Hello All- Did you know that the FDA approved Imfinzi for Extensive-Stage Small Cell Lung Cancer? Have you taken this? Have you found any difference in the results of your cancer?
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer
FDA Approves Imfinzi for Patients with Extensive-Stage Small Cell Lung Cancer
The Food and Drug Administration approved Imfinzi in combination with certain standard-of-care chemotherapies in extensive-stage small cell lung cancer, as the therapy improves median overall survival.

Ryan McDonald
March 30, 2020
The Food and Drug Administration (FDA) on Monday approved Imfinzi (durvalumab) as part of a combination treatment for extensive-stage small cell lung cancer (ES-SCLC). (cure magazine)

Imfinzi was approved in combination with etoposide plus either carboplatin or cisplatin, all considered standard-of-care chemotherapies, as a first-line treatment option for adults with ES-SCLC. Imfinzi, a human monoclonal antibody, counters the tumor's immune-evading tactics and releases the inhibition of immune responses.

Approximately two-thirds of patients diagnosed with small cell lung cancer (SCLC) are diagnosed with ES-SCLC, which means cancer has spread throughout the lung or to other parts of the body. Prognosis is rather poor, as 6% of all patients with SCLC will be alive five years after diagnosis.

“Patients with extensive-stage small cell lung cancer continue to face a poor prognosis and finding new medicines to improve outcomes in this setting has been a formidable challenge,” lead study author Dr. Jonathan Goldman, an associate professor of hematology and oncology at UCLA Medical Center, said in a press release. “The CASPIAN trial enables clinicians to choose durvalumab in combination with etoposide and either carboplatin or cisplatin, making this an important new first-line treatment option for patients that is both effective and well-tolerated.”

The FDA approved Imfinzi based on the results of a clinical trial involving 805 patients with ES-SCLC. Patients received either Imfinzi in combination with etoposide and either carboplatin or cisplatin chemotherapy or Imfinzi and chemotherapy with the addition of tremelimumab (an immune checkpoint blocker), versus chemotherapy alone.

The primary outcome of the trial, known as the phase 3 CASPIAN trial, was overall survival. Patients who received Imfinzi plus standard-of-care chemotherapy had a 27% lower risk of death and had a median overall survival of 13 months versus 10.3 months for patients who received standard-of-care chemotherapies alone.

We hope so!🙏🏻

@popkorhn- What a great morning this is for both of you! yayayay! Such wonderful news. I think that his positive attitude is carrying him into a wonderful future!

Pop’s treatment is working! His tumors shrunk after the two rounds of chemo and he finished his 3rd round. We are blessed that he has had no real side affects with only hair loss. Prior to the 4th round ,at the end of March, he will have another CT scan. 🙏🏻🙏🏻 His activity of 10,000 plus steps a day, seems to help.

@popkorhn- Am thinking about you and your visit yesterday. I hope that you hear some good news!

Thank you Merry. We are heading over to meet with his oncologist now. I appreciate the articles on sensitive Abdul relapse studies you sent over. We are praying too.🙏🏻